Promising Outlook for Verve Therapeutics: FDA Clearance and Strategic Partnership Drive Buy Rating

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report) and keeping the price target at $21.00.

Cory Jubinville, PhD’s rating is based on the recent FDA clearance of Verve Therapeutics’ IND application for their PCSK9 gene editing program, VERVE-102. This clearance is a significant milestone as it demonstrates regulatory confidence in the safety profile of VERVE-102, which is designed to treat heterozygous familial hypercholesterolemia and premature coronary artery disease.
The clearance allows for the expansion of VERVE-102’s clinical trials into the US, paving the way for larger Phase 2 and 3 studies. Additionally, the company’s strategic collaboration with Eli Lilly, which includes potential cost-sharing and profit-sharing arrangements, further strengthens the commercial prospects of VERVE-102. These factors combined suggest a promising outlook for Verve Therapeutics, justifying the Buy rating.

According to TipRanks, Jubinville, PhD is an analyst with an average return of -6.7% and a 34.78% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Tarsus Pharmaceuticals, and Crinetics Pharmaceuticals.